1. Home
  2. DCGO vs LUNG Comparison

DCGO vs LUNG Comparison

Compare DCGO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DocGo Inc.

DCGO

DocGo Inc.

HOLD

Current Price

$0.66

Market Cap

63.5M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.62

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCGO
LUNG
Founded
2015
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.5M
57.9M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
DCGO
LUNG
Price
$0.66
$1.62
Analyst Decision
Strong Buy
Buy
Analyst Count
4
7
Target Price
$2.38
$5.38
AVG Volume (30 Days)
523.9K
442.5K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$322,196,000.00
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
$6.77
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.45
$1.13
52 Week High
$1.78
$2.89

Technical Indicators

Market Signals
Indicator
DCGO
LUNG
Relative Strength Index (RSI) 54.60 62.46
Support Level $0.59 $1.22
Resistance Level $0.72 $1.64
Average True Range (ATR) 0.05 0.11
MACD 0.00 0.02
Stochastic Oscillator 52.84 65.61

Price Performance

Historical Comparison
DCGO
LUNG

About DCGO DocGo Inc.

DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has two reporting segments: Mobile Health Services and Transportation Services. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: